Cuorips (4894) · RiskMitigated
Unexpected health risks associated with regenerative medicine products
First written in FY2023. 1 of 2 entries say "Mitigated", first in FY2026. Latest entry: FY2026.
2entries
4years
0from disclosures
How it moved
Same theme, other companies
Unexpected health risks associated with regenerative medicine productsA theme 1 companies write about · 1 as a headwind · 0 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2026MitigatedAnnual report
「No adverse reactions or serious adverse reactions to the product were observed in this trial. The Pharmaceuticals and Medical Devices Agency determined that the safety of the product was acceptable.」
The company disclosed that no adverse reactions or serious adverse reactions were observed in the 8-subject trial and that PMDA judged the safety acceptable. Post-marketing evaluation covering 75 cases will continue. - FY2023First statedAnnual report
「It cannot be ruled out that health damage may occur during the clinical trial or even after marketing approval as a result of circumstances that could not have been anticipated or discovered during research and development or at the time of marketing approval.」
No manifest risk leading to serious health damage had been identified at that time, but the company disclosed safety risks including after approval.